Cargando…
CDH22 hypermethylation is an independent prognostic biomarker in breast cancer
BACKGROUND: Cadherin-like protein 22 (CDH22) is a transmembrane glycoprotein involved in cell-cell adhesion and metastasis. Its role in cancer is controversial because it has been described as being upregulated in colorectal cancer, whereas it is downregulated in metastatic melanoma. However, its st...
Autores principales: | Martín-Sánchez, Esperanza, Mendaza, Saioa, Ulazia-Garmendia, Ane, Monreal-Santesteban, Iñaki, Córdoba, Alicia, Vicente-García, Francisco, Blanco-Luquin, Idoia, De La Cruz, Susana, Aramendia, Ana, Guerrero-Setas, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270318/ https://www.ncbi.nlm.nih.gov/pubmed/28149335 http://dx.doi.org/10.1186/s13148-016-0309-z |
Ejemplares similares
-
CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer
por: Martín-Sánchez, Esperanza, et al.
Publicado: (2017) -
A DNA Methylation-Based Gene Signature Can Predict Triple-Negative Breast Cancer Diagnosis
por: Mendaza, Saioa, et al.
Publicado: (2021) -
ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer
por: Mendaza, Saioa, et al.
Publicado: (2020) -
Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis
por: Perez-Janices, Noemi, et al.
Publicado: (2015) -
Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC
por: Xue, Ruilin, et al.
Publicado: (2014)